Back pain and fatty liver disease are both common health concerns affecting women in the UK, yet the connection between them is frequently misunderstood. Fatty liver disease, or non-alcoholic fatty liver disease (NAFLD), affects up to one in three UK adults, with rising prevalence among women, particularly after menopause. Whilst fatty liver itself rarely causes back pain directly, women with this condition may experience discomfort for various reasons. Understanding the relationship between back pain, fatty liver symptoms in women, and when to seek medical attention is essential for appropriate management and early intervention to prevent progression of liver disease.

Understanding Fatty Liver Disease in Women

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates within liver cells. In the UK, non-alcoholic fatty liver disease (NAFLD) affects up to one in three adults, with prevalence increasing among women, particularly after menopause. The condition exists on a spectrum, ranging from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential liver damage. You may also encounter the newer term MASLD (metabolic dysfunction-associated steatotic liver disease), which is increasingly used alongside NAFLD.

NAFLD is defined by the presence of hepatic steatosis in people who consume little or no alcohol (within UK Chief Medical Officers' low-risk drinking guidelines of no more than 14 units per week). Women face unique risk factors for developing fatty liver disease. Hormonal changes during menopause appear to increase susceptibility, as oestrogen may offer some protective effects against hepatic fat accumulation; the sex difference in prevalence narrows after menopause. Additionally, polycystic ovary syndrome (PCOS), which is more prevalent in women, contributes to elevated risk through associated insulin resistance and metabolic dysfunction.

The pathophysiology involves insulin resistance as a central mechanism. When cells become less responsive to insulin, the liver increases fat production whilst simultaneously reducing fat breakdown. This metabolic dysfunction often coexists with other components of metabolic syndrome, including:

• Central obesity (particularly abdominal fat)

• Type 2 diabetes or prediabetes

• Hypertension

• Dyslipidaemia (abnormal cholesterol levels)

Most women with early-stage fatty liver disease remain asymptomatic, with the condition frequently discovered incidentally during routine blood tests showing elevated liver enzymes or during abdominal imaging performed for unrelated reasons. If you have risk factors for NAFLD, discuss assessment with your GP. Understanding these risk factors enables earlier identification and intervention, potentially preventing progression to more serious liver disease.

Can Fatty Liver Cause Back Pain?

The relationship between fatty liver disease and back pain is complex and often misunderstood. Simple steatosis (uncomplicated fatty liver) does not typically cause back pain. The liver itself has no pain receptors within its tissue (parenchyma), meaning fat accumulation alone does not generate pain signals. However, several mechanisms may explain why some women with fatty liver disease experience discomfort.

When the liver becomes significantly enlarged (hepatomegaly), the stretching of the liver capsule—the thin membrane surrounding the organ—can produce a sensation of fullness or discomfort in the right upper quadrant of the abdomen. This discomfort may occasionally radiate to the right shoulder or upper back through referred pain pathways involving the phrenic nerve. Such symptoms typically indicate more advanced disease or complications rather than simple steatosis.

It is crucial to recognise that back pain in women with fatty liver disease more commonly stems from unrelated musculoskeletal causes. The conditions that predispose to fatty liver—obesity, sedentary lifestyle, and metabolic syndrome—also increase risk for:

• Mechanical lower back pain from excess weight

• Degenerative disc disease

• Osteoarthritis of the spine

• Poor posture and muscular deconditioning

Additionally, gallbladder disease (such as gallstones or cholecystitis) is a common cause of right upper quadrant pain that may radiate to the right shoulder or back, and can coexist with fatty liver disease. Rarely, severe complications of advanced liver disease, such as liver abscess or acute hepatitis, may present with right upper quadrant or back pain, but these would be accompanied by other significant symptoms including fever, jaundice, or severe malaise.

Women experiencing persistent or severe back pain should seek medical evaluation to determine the underlying cause, rather than attributing it solely to fatty liver disease without proper assessment.

Recognising Fatty Liver Symptoms in Women

Early-stage fatty liver disease typically presents as a 'silent' condition, with most women experiencing no noticeable symptoms. When present, symptoms tend to be non-specific and easily attributed to other causes. Fatigue represents the most commonly reported symptom, described as persistent tiredness or reduced energy levels that don't improve with rest. This fatigue may result from metabolic dysfunction and insulin resistance rather than liver impairment itself.

Some women report a vague sensation of fullness or discomfort in the right upper abdomen, particularly after eating. This occurs beneath the right rib cage and may feel like a dull ache or heaviness. The sensation typically reflects liver enlargement rather than pain from the liver tissue itself. Occasionally, women describe a feeling of abdominal bloating or generalised digestive discomfort.

As fatty liver disease progresses to more advanced stages, additional features may emerge:

• Unintentional weight loss (in advanced disease)

• Mild nausea or loss of appetite

• Skin changes, including darkened patches (acanthosis nigricans) in skin folds—a marker of insulin resistance

It is important to emphasise that obvious signs of liver disease—such as jaundice (yellowing of skin and eyes), severe abdominal swelling (ascites), easy bruising, confusion or altered mental state, or spider naevi (small blood vessel clusters on the skin)—indicate advanced liver damage or cirrhosis and require urgent medical attention. These features are uncommon in simple fatty liver disease but may develop if the condition progresses untreated over many years.

If you have risk factors for fatty liver disease (such as obesity, type 2 diabetes, high cholesterol, or high blood pressure), discuss assessment with your GP. Early detection enables intervention before significant liver damage occurs, even in the absence of symptoms.

When Back Pain May Indicate Liver Problems

Whilst back pain alone rarely signals liver disease, certain characteristics and accompanying symptoms warrant medical evaluation. Right-sided upper back or shoulder pain that occurs alongside other liver-related symptoms deserves particular attention. This referred pain pattern results from irritation of the diaphragm or liver capsule, with pain signals transmitted through shared nerve pathways.

Red flag symptoms that suggest back pain may relate to liver or other serious pathology include:

• Pain accompanied by jaundice (yellowing of skin or whites of eyes)

• Fever, chills, or night sweats alongside back discomfort

• Unintentional weight loss

• Persistent nausea, vomiting, or loss of appetite

• Dark urine or pale-coloured stools

• Abdominal swelling or distension

• Easy bruising or bleeding

• Confusion or altered mental state

Women should seek urgent same-day medical attention (contact your GP urgently or attend A&E) if back pain is severe, sudden in onset, or accompanied by fever and jaundice, or any of the above red flag features. Such presentations may indicate complications including liver abscess, acute hepatitis, gallbladder disease, or even conditions unrelated to the liver such as kidney stones or pancreatitis.

For women with known fatty liver disease experiencing new or worsening back pain, a thorough assessment is essential to differentiate between common musculoskeletal causes and potential liver-related complications. Contact your GP if:

• Back pain is not improving after a few weeks (around six weeks) despite conservative measures

• Pain progressively worsens or changes in character

• You develop new symptoms alongside the back pain

• Pain interferes significantly with daily activities or sleep

Your GP can perform appropriate investigations to determine whether the pain relates to liver disease, musculoskeletal problems, or other causes, ensuring you receive appropriate treatment. Remember that most back pain in women with fatty liver disease stems from unrelated causes, but proper evaluation provides reassurance and appropriate management.

Diagnosis and Assessment of Fatty Liver Disease

Diagnosis of fatty liver disease in women typically begins with blood tests revealing elevated liver enzymes, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST). However, normal liver enzyme levels do not exclude fatty liver disease, as many women with significant hepatic steatosis maintain enzyme levels within the reference range. Additional blood tests assess liver function, lipid profile, glucose metabolism (HbA1c), and exclude other causes of liver disease such as viral hepatitis or autoimmune conditions.

Imaging investigations provide direct visualisation of liver fat. Ultrasound scanning represents the first-line imaging modality in the UK, offering a non-invasive, radiation-free method to detect hepatic steatosis. The characteristic 'bright liver' appearance on ultrasound indicates fat accumulation, though this technique cannot reliably quantify fat percentage or distinguish simple steatosis from NASH. Ultrasound sensitivity is lower in people with higher body mass index, and a normal ultrasound does not exclude steatosis. More advanced imaging options include:

• Transient elastography (FibroScan®): Measures liver stiffness as a marker of fibrosis whilst also quantifying fat content through controlled attenuation parameter (CAP)

• MRI-based techniques: Provide accurate fat quantification and assessment of liver architecture

• CT scanning: Can detect fatty liver but involves radiation exposure and is not routinely used for this purpose

According to NICE guidance (NG49), once NAFLD is confirmed in adults, the Enhanced Liver Fibrosis (ELF) blood test should be used to test for advanced fibrosis. An ELF score of 10.51 or above indicates probable advanced fibrosis and warrants specialist hepatology referral. In some UK primary care pathways, serum fibrosis scores such as FIB-4 or the NAFLD Fibrosis Score are used as initial tests; typical FIB-4 thresholds are less than 1.3 (low risk) and greater than 2.67 (higher risk) in adults under 65 years, or less than 2.0 and greater than 3.25 in those aged 65 and over. Local pathways may then use transient elastography or ELF as second-line tests. These non-invasive tests help stratify patients, identifying those requiring specialist hepatology referral versus those suitable for primary care management.

Liver biopsy, whilst the gold standard for definitive diagnosis and staging, is reserved for cases where:

• Non-invasive tests suggest advanced fibrosis

• Diagnostic uncertainty exists

• Coexisting liver conditions require clarification

For adults with NAFLD but without advanced fibrosis, NICE recommends reassessing fibrosis risk (for example, using the ELF test) every three years. Your GP or specialist will guide you on appropriate follow-up intervals based on your individual circumstances.

Treatment and Management Options for Women

Management of fatty liver disease in women centres on lifestyle modification as the primary therapeutic intervention. Currently, no medications are specifically licensed in the UK for treating NAFLD, making lifestyle changes the cornerstone of treatment. Weight loss represents the most effective intervention, with evidence demonstrating that losing 7–10% of body weight can significantly reduce liver fat, inflammation, and even reverse early fibrosis.

Dietary modifications should focus on:

• Reducing refined carbohydrates and added sugars, particularly sugar-sweetened beverages

• Adopting a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil

• Limiting saturated fats whilst incorporating omega-3 fatty acids from oily fish

• Reducing portion sizes to create a sustainable caloric deficit

• Avoiding excessive fructose from processed foods and fruit juices

Physical activity provides benefits independent of weight loss. NICE recommends at least 150 minutes of moderate-intensity aerobic activity weekly, combined with resistance training twice weekly. Even without significant weight reduction, regular exercise improves insulin sensitivity, reduces liver fat, and decreases cardiovascular risk.

Management of associated conditions is essential:

• Optimising control of type 2 diabetes according to diabetes guidelines (note: metformin is not recommended to treat NAFLD itself, but is used for glycaemic control as appropriate)

• Treating hypertension and dyslipidaemia according to cardiovascular risk

• Addressing obstructive sleep apnoea if present

• Managing PCOS in affected women

Alcohol advice: NICE guidance recommends that people with NAFLD stay within the UK Chief Medical Officers' low-risk drinking guidelines: no more than 14 units of alcohol per week, spread across three or more days, and avoiding binge drinking. Some specialists may advise complete abstinence in certain cases.

Medication considerations: Whilst no drugs are licensed specifically to treat NAFLD, certain medications show promise in selected patients. Pioglitazone and vitamin E have demonstrated benefits in some adults with biopsy-proven NASH, but their use is off-label, requires specialist hepatology supervision, and is restricted to carefully selected patients. Pioglitazone carries risks including weight gain, fluid retention, heart failure, and bone fractures; vitamin E is generally not recommended for people with diabetes. Women should avoid hepatotoxic substances and unnecessary medications.

Monitoring and follow-up involves regular assessment of liver enzymes, metabolic parameters, and fibrosis markers. For adults with NAFLD but without advanced fibrosis, NICE recommends reassessing fibrosis risk (for example, using the ELF test) every three years. Women with cirrhosis require specialist hepatology input and surveillance for complications including hepatocellular carcinoma (HCC); HCC surveillance is primarily offered to people with cirrhosis, with case-by-case consideration in advanced fibrosis under specialist care.

Referral to specialist services is appropriate when non-invasive tests suggest advanced fibrosis (for example, ELF score ≥10.51), when diagnostic uncertainty exists, or when disease progresses despite optimal lifestyle intervention. A multidisciplinary approach involving dietitians, diabetes specialists, and hepatologists optimises outcomes for women with fatty liver disease.

If you are taking any medicines and experience side effects, you can report them via the MHRA Yellow Card scheme at www.mhra.gov.uk/yellowcard or by searching for 'Yellow Card' in the Google Play or Apple App Store.

Frequently Asked Questions